Short answer
ORASURE TECHNOLOGIES INC (OSUR) filed its Q3 2025 10-Q quarterly report on Nov 5, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $27M (down 32.1% year over year) with net income of −$14M.
Q3 2025 key financials · XBRL
- Revenue
- $27M
- −32.1% YoY · −13.3% QoQ
- Net income
- −$14M
- −204.2% YoY · +30.4% QoQ
- Operating margin
- -59.4%
- Gross margin
- 43.5%
- EPS (diluted)
- −$0.19
- −216.7% YoY · +29.6% QoQ
Source: XBRL data from the ORASURE TECHNOLOGIES INC (OSUR) Q3 2025 10-Q on SEC EDGAR. USD.
ORASURE TECHNOLOGIES INC Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $27.1M, down 32% YoY from $39.9M
- Gross margin 43.5% vs 42.8% YoY; operating loss $16.1M vs $6.0M
- Best segment Diagnostics $14.5M; worst COVID-19 Diagnostics $0.09M, down 96% YoY
- Cash $216.5M vs $267.8M at December 31, 2024; operating cash use $40.0M
- Capital deployment: $10.0M common-stock repurchases; COVID-19 revenue expected to remain low through 2025 and foreseeable future
Risk Factors
- New trigger: October 1, 2025 government shutdown furloughed FDA and SEC employees and halted critical activities
- Regulatory review delays from FDA staffing reductions could postpone U.S. product development and commercialization timelines
- Federal workforce layoffs on October 10, 2025 suspended or delayed government-funded programs supporting operations
- Prolonged agency disruptions could prevent timely FDA inspections, reviews, approvals, and developer interactions
- No material changes to other 10-K risk factors beyond the supplemental government-agency disruption disclosure
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ORASURE TECHNOLOGIES INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.